Articles tagged with Hemoglobin
The American College of Physicians' AABB recommends a restrictive red blood cell transfusion strategy for stable adults and children, with evidence showing no difference in mortality or hospital stay between liberal and restrictive approaches. The guideline suggests considering transfusion at a hemoglobin threshold of 7-8 g/dL.
The FDA has revised labeling guidelines for erythropoiesis-stimulating agent (ESA) drugs in chronic kidney disease patients. These updates aim to minimize the risk of heart-related problems, but critics argue that they may be too conservative and not tailored to individual patient needs.
A University of Maryland study found that restricting blood transfusions after hip surgery did not harm patients and may even be unnecessary for some. The research included over 2,000 patients with anemia after hip fracture and showed no significant difference in recovery rates between those who received moderate transfusions and those...
A recent study has found that nearly a third of children with sickle cell disease have suffered silent strokes, highlighting the need to identify early signs of anemia and high blood pressure. Researchers believe anemia is the key factor contributing to these risk silent strokes.
A study by Christopher Golden found that lost access to bushmeat led to a 30% relative increase in malnutrition among children under 12, with iron deficiency anemia being the most prevalent form of malnutrition globally. The research suggests a balance between conservation and human health is needed.
A U-M study reveals Hemoglobin A1c test fails to identify children with diabetes, highlighting the need for improved nonfasting testing strategies. Researchers recommend using a nonfasting one-hour glucose challenge test or random glucose to identify children at risk of developing diabetes.
Researchers discovered that a degradation product of defective hemoglobin blocks the establishment of a trafficking system used by the malaria parasite, preventing circulatory disorders and neurological complications. The study provides new insights into the molecular mechanism behind the protective effect of sickle-cell anemia against...
A study found that children with sickle cell anemia are at risk for silent cerebral infarcts due to low hemoglobin levels, high systolic blood pressure, and male gender. The risk of silent strokes increases by age six, with over 25% of children suffering a stroke by then.
Two studies agree that diabetics with kidney failure shouldn't lower their blood glucose levels as much as those without kidney failure, suggesting a different optimal range. Hemoglobin A1C levels between 7% and 8% were found to be associated with the lowest risk of death for these patients.
Researchers have discovered a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease. Increasing the expression of proteins TR2 and TR4 more than doubled the level of fetal hemoglobin produced in sickle cell mice, reducing organ damage.
Researchers have discovered that hemoglobin interacts with HbA1 within living red blood cells, affecting the condition of patients with thalassemia and other diseases. The study also found a positive correlation between blood sugar levels and multiband re-release of Hbs from RBCs in diabetic individuals.
Researchers have corrected sickle cell disease in adult mice by activating the production of fetal hemoglobin, a protein that reduces the tendency of sickle hemoglobin to change red blood cells. This approach builds upon earlier studies and offers a new target for future therapies.
A study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute finds that deactivating the BCL11A protein can correct sickle cell disease in mice by activating fetal hemoglobin. The findings provide strong evidence that BCL11A could be a powerful treatment target for sickle cell disease and related blood disorders.
Scientists have identified a key player in regulating fetal hemoglobin levels, paving the way for new treatments of sickle cell disease. Silencing a specific protein called BCL11A can reactivate fetal hemoglobin production, effectively reversing the condition in adult mice.
Researchers found that patients who saw their doctors every two weeks had lower hemoglobin A1C levels, blood pressure and LDL cholesterol within a shorter timeframe compared to those who visited less frequently. This suggests that more frequent doctor-patient encounters can aid in achieving ideal treatment goals for diabetes.
Scientists at Virginia Tech and Penn have identified two enzymes, peptidases, as potential targets for new anti-malarial drugs. The researchers developed chemical genetic tools to specifically inhibit these enzymes, blocking hemoglobin degradation and starving the malaria parasite to death.
Patients with uncontrolled diabetes saw faster blood glucose, blood pressure, and cholesterol level control with more frequent primary care visits every two weeks. The study found that doubling the time between physician encounters increased median times to reach treatment targets by 35-87%.
Researchers created an artificial blood protein inspired by woolly mammoths' ability to conserve heat. The new hemoglobin can unload oxygen to tissues in cold conditions, making it suitable for use in hypothermia treatments during heart and brain surgeries.
Pomalidomide increases production of fetal hemoglobin, boosting red blood cells in patients with sickle cell disease. Unlike hydroxyurea, pomalidomide preserves bone marrow function without suppressing it.
A team of researchers has discovered that stored transfusion blood can accumulate 'free' hemoglobin and microparticles that react quickly with nitric oxide, leading to blood vessel constriction and hypertension. The findings suggest that a new approach to blood storage may be necessary to prevent complications.
Pediatric hematologist Mitchell J. Weiss and colleagues identified a rare hemoglobin mutation, named after the patient's hometown of Toms River, N.J., that causes temporary blue coloration and anemia. The mutation has mild effects and disappears within months of birth.
A study in C. elegans reveals that the tiny protein HRG-3 plays a crucial role in transporting heme to developing embryos and other parts of the worm's body. This finding holds promise for developing effective treatments against parasitic worms, which affect over a quarter of the world's population.
Research found a significant link between low vitamin D levels and anemia in children, with black children at higher risk due to lower vitamin D levels. The study suggests that vitamin D deficiency may play a role in the development of anemia in this population.
Researchers at Instituto Gulbenkian de Ciencia unravel the molecular mechanism of sickle cell trait's protective effect against malaria. Sickle hemoglobin induces heme oxygenase-1, which produces carbon monoxide to protect infected hosts from cerebral malaria.
A recent study found that daily iron supplements do not significantly increase hemoglobin levels in healthy pregnant women, but can help alleviate iron-poor blood conditions in Africa. Researchers followed over 1,000 pregnant women and discovered that all participants ended with similar iron levels after three months.
Children with acute anemia are at risk of undetected brain damage due to silent strokes, which can cause poor academic performance and severe cognitive impairments. Regular monitoring and timely transfusion may help prevent permanent brain damage in these children.
Patients with diabetes, kidney disease, and anemia who don't respond to treatment with darbepoetin alpha have a higher risk of cardiovascular disease or death. The study suggests customizing treatment based on initial response to the drug could reduce risk.
Dr. John Wood will investigate energy production mechanisms in red blood cells to determine if glutamine supplementation improves physiology in athletes with sickle cell trait. The goal is to develop an easy and safe therapy to incorporate into athletic training regimens.
A study of over 29,796 dialysis patients found that naturally high hemoglobin levels were not associated with increased mortality. In fact, the researchers discovered that patients with higher hemoglobin concentrations had a similar risk of dying as those with lower levels, after adjusting for other factors.
Researchers at Vanderbilt University have discovered that Staphylococcus aureus bacteria favor human hemoglobin over other animal hemoglobins, which may contribute to why some people are more susceptible to staph infections. Genetic variations in hemoglobin could be a key factor in individual susceptibility to these infections.
Researchers found that free heme released from red blood cells during infection causes organ failure, but hemopexin can neutralize its toxic effects. Administering hemopexin improves survival rates in mice and may predict mortality in patients with severe sepsis.
A study of 5037 European hemodialysis patients found that fluctuating hemoglobin levels do not increase the risk of mortality. Patients with consistently low hemoglobin levels had a higher risk of dying, however.
Researchers at Tel Aviv University discovered that low hemoglobin levels can indicate a potential for colon cancer years before it's diagnosed. A continuous long-term decline of more than 0.28 grams per decilitre over a four-year period may serve as a warning of illness on the horizon.
A study of 24,875 dialysis patients found that sustained extremes in blood sugar levels increased the risk of dying prematurely. Individualized hemoglobin A1c targets may be more appropriate than a one-size-fits-all approach for diabetic patients with kidney failure.
Researchers found that discontinuing epoetin was more effective than reducing dose in normalizing hemoglobin levels, but also increased risk of lower-than-recommended levels. Study results suggest a balance between administering epoetin and achieving target hemoglobin levels is necessary for kidney disease patients.
Researchers discovered an adaptation in Eastern mole blood that allows for more efficient carbon dioxide transport, facilitating burrowing. The 'super hemoglobin' enables moles to thrive underground, overcoming oxygen and carbon dioxide challenges.
A study found that deleting a viral element from human genes can increase production of fetal hemoglobin in red blood cells, which could help alleviate symptoms of sickle cell disease. The researchers believe this natural mechanism may be the key to developing targeted therapies for patients.
A comparison of Tibetan and Han Chinese genomes reveals over 30 genes with DNA mutations associated with high-altitude adaptation. The fastest genetic change ever observed has allowed Tibetans to thrive at high altitudes without the problems faced by people from lower elevations.
A new study by Johns Hopkins Medicine reveals that black children with chronic kidney disease have more severe anemia than white children, even when treated equally. The research suggests that genetic variations may be at play and could require tailored treatment guidelines.
The NHLBI and CDC are launching a four-year pilot project to study sickle cell disease and thalassemias in six US states. The Registry and Surveillance System in Hemoglobinopathies (RuSH) project aims to gather comprehensive demographic data on people with these life-threatening diseases.
A recent study published in JAMA found that most primary care physician practices have too few patients to reliably measure quality and cost performance. The researchers analyzed data from over 2005 Medicare Part B and found that only a small percentage of practices had sufficient caseloads to detect significant differences in common m...
Researchers at Boston Children's Hospital have found a promising new approach to treating sickle cell disease by silencing a gene that suppresses fetal hemoglobin production. Inactivating the BCL11A gene led to a significant increase in gamma-globin production, potentially compensating for defective adult hemoglobin.
Researchers have made significant breakthroughs in understanding the genetic basis of sickle cell disease, exploring the potential of activating fetal hemoglobin to reduce complications. A new study found that activating BCL11A could lead to increased production of healthy hemoglobin, providing a promising avenue for treatment.
A team of scientists led by Ross Hardison has made significant discoveries about the mechanisms of gene regulation in red blood cells. They found that transcription factor GATA-1 controls the expression of over 2,600 genes by binding to specific sites on DNA.
A genetic study has identified a significant link between the TMPRSS6 gene and hemoglobin regulation, with potential implications for treating chronic hemoglobin problems. The research found a strong association between the gene and hemoglobin levels in 16,000 people of European and Indian Asian ancestry.
Researchers have identified the molecular basis of high-altitude adaptation in deer mice, discovering specific mutations in hemoglobin genes that enable them to tolerate chronic hypoxia. These mutations increase oxygen-binding affinity, allowing animals to survive in low-oxygen environments such as the top of Mount Evans.
Studies found that partial correction of severe anemia with erythropoietin improves heart structure, while normalization of hemoglobin levels reduces fatigue in kidney disease patients. However, treating to a normal hemoglobin level may cause harm and is not recommended for all patients.
Scientists have found a genetic variation at the hexokinase-1 gene associated with glycated hemoglobin, an index of long-term blood glucose concentration. The study analyzed 14,618 women and found that variations at this gene are an important determinant of glycated hemoglobin concentrations.
Researchers studied the quality of care for hospitalized sickle cell disease patients, finding that hospitals treating low volumes have higher mortality rates. The study also identified associations between insurance coverage, patient socioeconomic status, and reduced hospital stays.
Researchers have identified a gene that directly affects the production of fetal hemoglobin, which could lead to the development of new therapies for sickle cell disease and thalassemia. By suppressing a specific gene called BCL11A, HbF production improves dramatically, providing a potential new target for treatments.
Researchers at St. Jude Children's Research Hospital have developed a gene therapy that alleviates sickle cell disease pathology by introducing a corrective gene into mouse blood cells. The treated mice showed essentially no difference from normal mice, with improved red blood cell production and organ function.
A study found that preventing anemia in kidney disease patients is crucial for their physical and mental health. The researchers recommend that treatment should be initiated at lower hemoglobin levels to improve quality of life, contrary to current FDA statements.
Researchers identified five gene variants that could predict sickle cell disease severity and offer potential therapeutic targets. These variants influence fetal hemoglobin levels, which affect symptom severity in the disease.
Researchers at the University of Bonn have identified a new hemoglobin type that appears to transport less oxygen than normal. This discovery was made after examining two patients with low oxygen levels in their blood, who did not show any signs of cardiac defects. The new type of haemoglobin, named Haemoglobin Bonn, can distort oxygen...
Researchers have identified a novel small molecule therapy called senicapoc that shows efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia. Senicapoc, a Gardos channel blocker, works by limiting solute and water loss, thereby preserving RBC hydration.
Researchers discovered a genetic variant in the BCL11A gene associated with higher levels of fetal hemoglobin and milder beta-thalassemia symptoms. This finding has implications for developing targeted therapies to alleviate hemoglobin deficiencies in people with beta-thalassemia and sickle cell anemia.
A recent study published in the Clinical Journal of the American Society of Nephrology suggests that persistently low hemoglobin levels in dialysis patients increase their risk of death, while fluctuating levels do not. The research used data from nearly 160,000 patients to analyze the effects of hemoglobin variability on mortality rates.
Researchers developed a new indicator, Hb-Var, measuring hemoglobin level stability in dialysis patients, finding it strongly predicts mortality risk. Higher Hb-Var scores associated with increased death rates, even after adjusting for absolute hemoglobin levels and trends.
A team of researchers has made a breakthrough in understanding the mechanisms that regulate hemoglobin's ability to transport oxygen. By using sophisticated atomic calculation techniques, they have identified the factors that control hemoglobin's affinity for oxygen, which can now be used to design alterations of its structure.
A team of researchers from Wake Forest University has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that converts nitrite salt to the vasodilator nitric oxide. This reaction mechanism could have far-reaching implications for treating cardiovascular diseases.